Wolf-henning Prof. Dr. Boehncke

Wolf-henning Prof. Dr. Boehncke's AcademicInfluence.com Rankings

Philosophy

#8148

World Rank

#11474

Historical Rank

Logic

#5178

World Rank

#6556

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Wolf-henning Prof. Dr. Boehncke's Degrees

Doctorate Medicine University of Cologne

Why Is Wolf-henning Prof. Dr. Boehncke Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Wolf-henning Prof. Dr. Boehncke's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Treatment recommendations for psoriatic arthritis (2008) (796)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis (2016) (764)
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update (2020) (433)
The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity (2011) (431)
Psoriasis: a possible risk factor for development of coronary artery calcification (2007) (359)
S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update (2012) (259)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus‐Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis (2018) (255)
The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond (2018) (249)
Psoriasis patients show signs of insulin resistance (2007) (239)
Proteasome inhibition: a new anti-inflammatory strategy (2003) (231)
Biological therapies in the systemic management of psoriasis: International Consensus Conference (2004) (214)
Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. (2004) (198)
The role of IL‐23 and the IL‐23/TH17 immune axis in the pathogenesis and treatment of psoriasis (2017) (172)
Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences (2018) (171)
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial (2020) (145)
Etiology and Pathogenesis of Psoriasis. (2015) (140)
Pulling the trigger on psoriasis (1996) (137)
The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. (2003) (136)
Treatment of psoriasis by topical photodynamic therapy with polychromatic light (1994) (135)
Managing comorbid disease in patients with psoriasis (2010) (132)
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study (2018) (130)
Mycophenolate mofetil is effective in the treatment of atopic dermatitis. (2001) (126)
Excess β2 microglobulin promoting functional peptide association with purified soluble class I MHC molecules (1991) (125)
Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. (2004) (123)
Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation (2002) (120)
Effective continuous systemic therapy of severe plaque‐type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study (2011) (120)
The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition. (1993) (119)
Familial juvenile onset psoriasis is associated with the human leukocyte antigen (HLA) class I side of the extended haplotype Cw6-B57-DRB1*0701-DQA1*0201-DQB1*0303: a population- and family-based study. (1996) (119)
Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. (2002) (117)
Is psoriasis a T‐cell disease? (2000) (111)
Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases. (2002) (111)
S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatment (2018) (111)
Burden of Disease: Psoriasis and Psoriatic Arthritis (2013) (110)
The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo (2006) (109)
German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version) (2007) (109)
Specific TRPC6 Channel Activation, a Novel Approach to Stimulate Keratinocyte Differentiation* (2008) (107)
Junctional adhesion molecules (JAM)-B and -C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation. (2005) (101)
German S3-guidelines on the treatment of psoriasis vulgaris (short version) (2012) (100)
IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications (2020) (99)
Biologic therapies for psoriasis. A systematic review. (2006) (96)
Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris (1999) (95)
Evidence‐based (S3) guidelines for the treatment of psoriasis vulgaris (2007) (94)
S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011 (2011) (90)
Interleukin-1β interferes with epidermal homeostasis through induction of insulin resistance: implications for psoriasis pathogenesis. (2012) (86)
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement (2020) (85)
Incidence and causes of heparin-induced skin lesions (2009) (83)
German psoriasis registry PsoBest: objectives, methodology and baseline data (2014) (79)
Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis (2014) (77)
Oligonucleotide typing reveals association of type I psoriasis with the HLA-DRB1*0701/2, -DQA1*0201, -DQB1*0303 extended haplotype. (1993) (77)
Systemic photodynamic therapy is a safe and effective treatment for psoriasis. (2000) (75)
Reduced TRPC Channel Expression in Psoriatic Keratinocytes Is Associated with Impaired Differentiation and Enhanced Proliferation (2011) (71)
Clinical use of dimethyl fumarate in moderate‐to‐severe plaque‐type psoriasis: a European expert consensus (2018) (71)
P-selectin (2007) (71)
Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial (2011) (69)
Therapy of psoriasis in childhood and adolescence ‐ a German expert consensus (2011) (68)
Keratinocyte-Derived IL-17E Contributes to Inflammation in Psoriasis. (2016) (68)
Narrowband UV-B phototherapy in the treatment of cutaneous graft versus host disease. (2002) (66)
Calcipotriol Solution for the Treatment of Scalp Psoriasis: Evaluation of Efficacy, Safety and Acceptance in 3,396 Patients (2001) (66)
Cardiovascular Mortality in Psoriasis and Psoriatic Arthritis: Epidemiology, Pathomechanisms, Therapeutic Implications, and Perspectives (2012) (66)
Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. (2000) (64)
Cathepsin S activity is detectable in human keratinocytes and is selectively upregulated upon stimulation with interferon-gamma. (2002) (63)
Efficacy of dexpanthenol in skin protection against irritation: a double‐blind, placebo‐controlled study (2003) (62)
Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis. (2004) (62)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015 (2015) (61)
Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. (2008) (61)
Platelet P‐selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis (2009) (60)
Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice (2019) (59)
Neutralization of Macrophage Migration Inhibitory Factor (MIF) by Fully Human Antibodies Correlates with Their Specificity for the β-Sheet Structure of MIF* (2012) (58)
Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin (2013) (56)
Leg ulcers in Klinefelter's syndrome – further evidence for an involvement of plasminogen activator inhibitor‐1 (1997) (56)
Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides (2005) (55)
Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment (2018) (55)
Anti‐inflammatory effects of the GABAB receptor agonist baclofen in allergic contact dermatitis (2010) (55)
Promoting patient‐centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience (2015) (55)
Juvenile psoriasis and its clinical management: a European expert group consensus (2010) (55)
Photodynamic therapy in psoriasis: suppression of cytokine production in vitro and recording of fluorescence modification during treatment in vivo (2004) (55)
Heparin-induced skin lesions (2012) (53)
Inflammation dependent mTORC1 signaling interferes with the switch from keratinocyte proliferation to differentiation (2017) (52)
The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity. (2006) (51)
Junctional adhesion molecule (JAM)‐B supports lymphocyte rolling and adhesion through interaction with α4β1 integrin (2009) (50)
Induction of psoriasiform inflammation by a bacterial superantigen in the SCID‐hu xenogeneic transplantation model (1997) (49)
IL-25 (IL-17E) in epithelial immunology and pathophysiology. (2021) (48)
Allergic contact dermatitis from black cumin (Nigella sativa) oil‐containing ointment (2002) (47)
Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus (2006) (47)
Management of cutaneous type IV hypersensitivity reactions induced by heparin (2006) (47)
Immunogenicity of biologic therapies: causes and consequences (2018) (46)
Tolerance to intravenous admiration of heparin and heparinoid in a patient with delayed‐type hypersensitivity to heparins and heparinoids (1996) (46)
Heparin‐induced non‐necrotizing skin lesions: rarely associated with heparin‐induced thrombocytopenia (2010) (44)
Swiss clinical practice guidelines on field cancerization of the skin. (2014) (43)
S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 2 – Special patient populations and treatment situations (2018) (43)
Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature (2007) (42)
Efalizumab in the treatment of psoriasis (2007) (42)
Endogenous μ‐opioid peptides modulate immune response towards malignant melanoma (2011) (42)
T-Cell-Receptor Repertoire in Chronic Plaque-Stage Psoriasis Is Restricted and Lacks Enrichment of Superantigen-Associated Vβ Regions (1995) (41)
Methylprednisolone blocks autoantibody-induced tissue damage in experimental models of bullous pemphigoid and epidermolysis bullosa acquisita through inhibition of neutrophil activation. (2013) (41)
Psoriasiform architecture of murine epidermis overlying human psoriatic dermis transplanted onto SCID mice (2004) (40)
The SCID-hu xenogeneic transplantation model allows screening of anti-psoriatic drugs (1999) (39)
Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans (2003) (39)
Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris (2016) (38)
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure (2019) (38)
Psoriasis – a systemic inflammatory disorder: clinic, pathogenesis and therapeutic perspectives (2009) (38)
Clonal disease in early cutaneous T-cell lymphoma. (1994) (38)
Diminished thrombus formation and alleviation of myocardial infarction and reperfusion injury through antibody- or small-molecule-mediated inhibition of selectin-dependent platelet functions. (2007) (38)
Ethanol metabolite acetic acid as causative agent for type‐I hypersensitivity‐like reactions to alcohohc beverages (1996) (37)
High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy. (2013) (37)
Differential expression of heat shock protein 70 (HSP70) and heat shock cognate protein 70 (HSC70) in human epidermis (2004) (36)
Role of beta 1-integrins in epidermotropism of malignant T cells. (1992) (36)
Genetic control of psoriasis is relatively distinct from that of metabolic syndrome and coronary artery disease (2013) (36)
Autoreactive T-Lymphocytes in Inflammatory Skin Diseases (2019) (36)
Patient perceptions of clear/almost clear skin in moderate‐to‐severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey (2018) (36)
A Subset of Macrophages Located along the Basement Membrane (“Lining Cells”) Is a Characteristic Histopathological Feature of Psoriasis (1995) (36)
Topology of psoriasis in routine care: results from high‐resolution analysis of 2009 patients (2019) (36)
IL-22 capacitates dermal fibroblast responses to TNF in scleroderma (2015) (36)
Immature mast cells exhibit rolling and adhesion to endothelial cells and subsequent diapedesis triggered by E‐ and P‐selectin, VCAM‐1 and PECAM‐1 (2010) (35)
Experimental approaches to lymphocyte migration in dermatology in vitro and in vivo (2005) (35)
Eosinophilic cellulitis (Wells' syndrome) associated with colon carcinoma (2005) (35)
Differential expression of adhesion molecules on infiltrating cells in inflammatory dermatoses. (1992) (34)
IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation. (2019) (33)
Diagnosing and treating psoriatic arthritis: an update (2014) (33)
Antibodies to desmogleins 1 and 3, but not to BP180, induce blisters in human skin grafted onto SCID mice (2001) (33)
Interfering with leukocyte rolling--a promising therapeutic approach in inflammatory skin disorders? (2003) (32)
Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities. (2006) (32)
[S3-Guidelines for the therapy of psoriasis vulgaris]. (2006) (32)
Photodynamic tumor therapy and on-line fluorescence spectroscopy after ALA administration using 633-nm light as therapeutic and fluorescence excitation radiation (1994) (32)
PS3, a semisynthetic beta-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions. (2009) (32)
Low allergenic potential with fondaparinux: results of a prospective investigation. (2010) (31)
Reproducible identification of the causative drug of a fixed drug eruption by oral provocation and lesional patch testing (2002) (31)
In vitro and in vivo effects of photodynamic therapy in cutaneous T cell lymphoma. (1994) (31)
Immunomodulatory drugs for psoriasis (2003) (30)
Allergic contact dermatitis from benzyl alcohol during topical antimycotic treatment (1999) (30)
Leukocyte extravasation as a target for anti‐inflammatory therapy – Which molecule to choose? (2005) (29)
Cardiovascular Comorbidities in Psoriasis and Psoriatic Arthritis: Pathogenesis, Consequences for Patient Management, and Future Research Agenda: A Report from the GRAPPA 2009 Annual Meeting (2011) (29)
Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation (2002) (29)
Psoriasis and bacterial superantigens--formal or causal correlation? (1996) (29)
The SCID-hu xenogeneic transplantation model: complex but telling (1999) (28)
Regulatory cells in the skin: Pathophysiologic role and potential targets for anti-inflammatory therapies. (2019) (28)
Expression of the basal cell adhesion molecule (B‐CAM) in normal and diseased human skin (2000) (28)
Diminished lymphocyte adhesion and alleviation of allergic responses by small-molecule- or antibody-mediated inhibition of L-selectin functions. (2007) (28)
Cost‐effectiveness of psoriasis therapy with etanercept in Germany (2007) (27)
Cytokines of the IL‐17 family in psoriasis (2020) (27)
Influence of activation and differentiation of cells on the effectiveness of photodynamic therapy. (1995) (27)
Clinical and pathophysiological aspects of hydroxyethyl starch-induced pruritus: evaluation of 96 cases. (1996) (27)
Safety and efficacy of alefacept in elderly patients and other special populations. (2005) (27)
Intolerance of fondaparinux in a patient allergic to heparins (2004) (27)
Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT (2017) (27)
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis (2021) (26)
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced (2021) (26)
Gene-diet interactions associated with complex trait variation in an advanced intercross outbred mouse line (2019) (25)
Microdialysis documents changes in the micromilieu of psoriatic plaques under continuous systemic therapy (2011) (25)
Comparison of sensitivity towards photodynamic therapy of cutaneous resident and infiltrating cell types in vitro (1996) (25)
OP0218 Efficacy and safety results of guselkumab, an anti-il23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double-blind, placebo-controlled study (2017) (25)
More than skin-deep: the many dimensions of the psoriatic disease. (2014) (25)
The Western blot is a highly sensitive and efficient technique in diagnosing allergy to wasp venom (2001) (24)
IL‐17A localizes in the exocytic compartment of mast cells in psoriatic skin (2017) (24)
Topical photodynamic therapy using methylene blue and 5-aminolaevulinic acid in psoriasis (1997) (24)
The risk for cross‐reactions after a cutaneous delayed‐type hypersensitivity reaction to heparin preparations is independent of their molecular weight: a systematic review (2011) (23)
Circadian clocks guide dendritic cells into skin lymphatics (2021) (23)
Interactive large-group teaching in a dermatology course (2006) (23)
T‐cell receptor β variable region (Vβ) usage in cutaneous T‐cell lymphomas (CTCL) in comparison to normal and eczematous skin (1996) (23)
Allergic contact dermatitis from diphenylthiourea in a Wet suit (1997) (23)
Cardiovascular Comorbidities of Psoriasis and Psoriatic Arthritis: A Report from the GRAPPA 2012 Annual Meeting (2013) (22)
PAX2 Regulates ADAM10 Expression and Mediates Anchorage-Independent Cell Growth of Melanoma Cells (2011) (21)
Type‐IV hypersensitivity to topical estradiol in a patient tolerant to it orally (1996) (21)
Benzoyl peroxide as a contact allergen in adhesive tape (1999) (21)
Psoriasis and risk of myocardial infarction. (2007) (21)
Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases (2005) (21)
Psoriasis: Clinical manifestations, pathogenesis and therapeutic perspectives. (2005) (20)
Benchmarking Care in Psoriatic Arthritis — The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting (2017) (20)
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. (2020) (20)
ADAM15 expression is downregulated in melanoma metastasis compared to primary melanoma. (2010) (20)
Structure-function relation of efomycines, a family of small-molecule inhibitors of selectin functions. (2006) (20)
New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease (2014) (19)
The psoriasis SCID mouse model: a tool for drug discovery? (2005) (19)
Alopecia areata but not androgenetic alopecia is characterized by a restricted and oligoclonal T‐cell receptor‐repertoire among infiltrating lymphocytes (1997) (19)
The superantigen exfoliative toxin induces cutaneous lymphocyte-associated antigen expression in peripheral human T lymphocytes. (1996) (19)
Analysis of TAP2 and HLA-DP gene polymorphism in psoriasis. (1994) (19)
The International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: A Report from the GRAPPA 2013 Meeting (2014) (19)
Cardiovascular Diseases in Psoriasis and Psoriatic Arthritis (2019) (19)
[Endurance capabilities of triathlon competitors with type 1 diabetes mellitus]. (2009) (19)
Quality indicators in psoriatic arthritis. (2007) (19)
Targeting selectin functions in the therapy of psoriasis. (2004) (18)
Occupational protein contact dermatitis caused by meat and fish. (1998) (18)
[Comorbidity in psoriasis]. (2016) (18)
Predominant usage of distinct T‐cell receptor Vβ regions by epidermotropic T cells in psoriasis (1994) (18)
Psoriasis and Psoriatic Arthritis: Flip Sides of the Coin? (2016) (17)
German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: Treatment goals and treatment recommendations (2021) (17)
IL-17E (IL-25) and IL-17A differentially affect the functions of human keratinocytes. (2020) (17)
Leukocyte adhesion: a suitable target for anti-inflammatory drugs. (2006) (17)
Platelet, not endothelial, P-selectin expression contributes to generation of immunity in cutaneous contact hypersensitivity. (2010) (17)
Tolerance of fondaparinux in patients with generalized contact dermatitis to heparin (2008) (17)
Cardiovascular morbidity in psoriasis: epidemiology, pathomechanisms, and clinical consequences. (2008) (16)
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study (2020) (16)
Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults (2020) (16)
Demonstration of Clonal Disease in Early Mycosis Fungoides (1992) (16)
Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis–severe combined immunodeficient mouse model (2005) (15)
Superantigens but not mitogens are capable of inducing upregulation of E‐selectin ligands on human T lymphocytes (1997) (15)
Prospective randomised comparison of traditional, personal bedside and problem‐oriented practical dermatology courses (2004) (15)
Delayed-type hypersensitivity reaction to kava-kava extract. (2000) (15)
Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry (2017) (15)
Safety and Efficacy of Therapies for Skin Symptoms of Psoriasis in Patients with Psoriatic Arthritis: A Systematic Review (2014) (14)
Evidence‐based (S3) guideline for the treatment of psoriasis vulgaris – Update: “Therapeutic options” and “Efalizumab” (2010) (14)
Reversal of murine epidermal atrophy by topical modulation of calcium signaling. (2014) (14)
Targeted cutaneous delivery of etanercept using Er:YAG fractional laser ablation. (2020) (14)
The selective cyclooxygenase‐2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria (2003) (14)
The Dermatologists' Role in Managing Psoriatic Arthritis: Results of a Swiss Delphi Exercise Intended to Improve Collaboration with Rheumatologists (2015) (13)
[Osteoma cutis. Multiple miliary osteoma of the face]. (1993) (13)
Insulin Resistance May Contribute to Upregulation of Adhesion Molecules on Endothelial Cells in Psoriatic Plaques. (2016) (13)
Interleukin-38 interacts with destrin/actin-depolymerizing factor in human keratinocytes (2019) (13)
Eukaryotic expression of the broad‐spectrum chemokine receptor antagonist vMIP‐II and its effects on T‐cell function in vitro and in vivo (2006) (13)
Type I and type II psoriasis show a similar usage of T-cell receptor variable regions. (1991) (12)
Biologics in General Medicine (2007) (12)
Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population Survey (2020) (12)
Application, tolerance and safety of fondaparinux therapy in a German hospital: a prospective single-centre experience. (2012) (12)
Recognition of early melanoma: a monocentric dermoscopy follow‐up study comparing de novo melanoma with nevus‐associated melanoma (2018) (12)
C-type particles are inducible in Se-Ax, a continuous T-cell line from a patient with Sézary's syndrome (2004) (12)
German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations (2021) (11)
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health‐related quality of life from two randomized phase 3 studies (2020) (11)
[New information about fumaric acid esters (Fumaderm): results of a workshop of experts]. (2011) (11)
Diagnosis of heparin-induced delayed type hypersensitivity (2010) (11)
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis (2021) (11)
Prologue: 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2013) (11)
Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care (2020) (11)
Changes in the sex hormone profile of male patients with moderate-to-severe plaque-type psoriasis under systemic therapy: results of a prospective longitudinal pilot study (2011) (11)
Dysfunctional Keratinocytes Increase Dermal Inflammation in Systemic Sclerosis: Results From Studies Using Tissue‐Engineered Scleroderma Epidermis (2021) (11)
The T-cell receptor Vβ repertoire of nickel-specific T cells (1998) (10)
The influence of heparin’s molecular weight and the incidence of delayed type hypersensitivity reactions revisited; in response to Grims et al., Br J Dermatol 2007; 157:514–17 (2008) (10)
Chronic venous insufficiency – a potential trigger for localized scleroderma (2006) (10)
Antagonistic effects of the staphylococcal enterotoxin a mutant, SEA(F47A/D227A), on psoriasis in the SCID-hu xenogeneic transplantation model. (2001) (10)
Endothelial cells are highly heterogeneous at the level of cytokine‐induced insulin resistance (2013) (10)
Skin Involvement in Psoriatic Arthritis Worsens Overall Disease Activity, Patient-Reported Outcomes, and Increases Healthcare Resource Utilization: An Observational, Cross-Sectional Study (2018) (10)
EADV preceptorship: advances in dermatology (2010) (10)
OP0308 Efficacy and safety results of guselkumab in patients with active psoriatic arthritis over 56 weeks from a phase 2a, randomised, double-blind, placebo-controlled study (2018) (10)
Epidemiology and Potential Pathomechanisms of Cardiovascular Comorbidities in Psoriasis: A Report from the GRAPPA 2010 Annual Meeting (2012) (10)
The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development (2019) (9)
Evidence for a Pathway Independent from 2′‐Deoxyguanosine and Reversible by IL‐2 by which Purine Nucleoside Phosphorylase Inhibitors Block T‐Cell Proliferation (1994) (9)
Dermal adipocytes’ claim for fame in psoriasis (2017) (9)
Prologue: 2013 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2014) (9)
Association between clinical specialty setting and disease management in patients with psoriatic arthritis: results from LOOP, a cross‐sectional, multi‐country, observational study (2020) (9)
Urticaria associated with a small cell carcinoma of the lung. (2002) (9)
Monitoring of phagocytic activity in histiocytic cytophagic panniculitis. (2001) (9)
Managing comorbidities in psoriasis. (2009) (9)
T-cell receptor beta variable region (V beta) usage in cutaneous T-cell lymphomas (CTCL) in comparison to normal and eczematous skin. (1996) (9)
[Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs)]. (2005) (8)
Constitutive and functionally relevant expression of JAM-C on platelets (2010) (8)
Computer‐aided analysis of cell interactions under dynamic flow conditions (2009) (8)
Ablative techniques in Psoriasis vulgaris resistant to conventional therapies. (1999) (8)
Low incidence of heparin‐induced skin lesions in orthopedic surgery patients with low‐molecular‐weight heparins (2018) (8)
Psoriasis treatment: current and emerging directed therapies. Discussion (2005) (8)
Association of sex and systemic therapy treatment outcomes in psoriasis: a two‐country, multicentre, prospective, noninterventional registry study * (2021) (8)
NAGELLACK-ALLERGIE: EINE WICHTIGE DIFFERENTIALDIAGNOSE BEI KONTAKTDERMATITIS (2008) (8)
Overexpression of the human antigen R suppresses the immediate paradoxical proliferation of melanoma cell subpopulations in response to suboptimal BRAF inhibition (2017) (8)
Intolerance to sodium metabisulfite in beer (1996) (8)
Prologue: 2014 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2015) (7)
Discrimination between immunoaccessory and phagocytic monocytes/macrophages of the skin in paraffin‐embedded tissue by the monoclonal antibody Ki‐M1P (1993) (7)
Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial (2020) (7)
T-cell-receptor repertoire in chronic plaque-stage psoriasis is restricted and lacks enrichment of superantigen-associated V beta regions. (1995) (7)
Chapter 16 Topical photodynamic therapy for psoriasis (2001) (7)
Complicated mycosis fungoides mimicking facial erysipelas (2005) (7)
Eyelid dermatitis caused by an eyelash former (2005) (7)
IL‐38 orchestrates proliferation and differentiation in human keratinocytes (2022) (7)
Fixed drug eruption caused by articain (2004) (6)
Psoriatic Arthritis and Psoriasis (2016) (6)
Viewpoint 1 (2005) (6)
Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care (2020) (6)
The alpha-defensins HNP-1 and HNP-2 are dominant self-peptides presented by HLA class-II molecules in lesional psoriatic skin. (2004) (6)
Graft persistence in animal models of psoriasis (1997) (6)
Perspective: Don't be superficial (2012) (6)
Biosimilars for Psoriasis—Experience from Europe (2019) (5)
Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab". (2010) (5)
Prologue: 2015 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2016) (5)
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies (2022) (5)
Delayed‐type reactivity to catcipotriol without cross‐sensitization to tacalcitol (1997) (5)
Kutane Botryomykose (2007) (5)
Mechanotransduction in Skin Inflammation (2022) (5)
Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial (2019) (5)
[Nail polish allergy. An important differential diagnosis in contact dermatitis]. (1997) (5)
Heavy naphthen oil exhibits antipsoriatic efficacy in vivo and antiproliferative as well as differentiation-inducing effects on keratinocytes in vitro. (2000) (5)
[Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents]. (2001) (5)
Research in practice: the systemic aspects of psoriasis (2008) (5)
[Cutaneous botryomycosis. A rarely diagnosed bacterial infection of the skin]. (2007) (5)
New biologics in psoriasis – progress and problems (2017) (5)
Discussion: Assessment of psoriatic arthritis (2005) (5)
Photodynamic tumor therapy and on-line fluorescence spectroscopy after aminolevulinic acid administration using 633-nm light as therapeutic and fluorescence excitation radiation (1994) (4)
Biologic effects of bacterial superantigens in a xenogeneic transplantation model for psoriasis. (2001) (4)
GRAPPA Fellows Symposium Adjacent to the European Academy of Dermatology and Venerology Meeting, Verona, 2012: A Meeting Report (2013) (4)
In-vivo remission spectroscopy on tattoos and topically applied photosensitizers in man (1994) (4)
[New insights into fumaric acid esters (Fumaderm ®):results of the 2nd Expert Workshops]. (2012) (4)
[The selective cyclooxygenase-2 inhibitor celecoxib is a safe alternative in patients with pseudo-allergic reactions to nonsteroidal anti-inflammatory drugs]. (2003) (4)
Anaphylaxis to red currants (2000) (4)
Introduction: Definition and Classification of Biologics (2007) (4)
Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation (2002) (4)
GRAPPA 2013 Basic/Translational/Clinical Science Update: Comorbidity Monitoring (2014) (4)
[Beyond immunopathogenesis. Insulin resistance and "epidermal dysfunction"]. (2012) (4)
GRAPPA 2015 Research and Education Project Reports (2016) (4)
Tolerance to a group C corticosteroid systemically in a patient with delayed‐type hypersensitivity to group A systemic corticosteroids (2002) (4)
Warning Shot (2001) (4)
[Modern therapy of psoriasis : evidence-based, patient-centered, goal-oriented]. (2012) (4)
‘Upgrading’ psoriasis responsibly (2014) (4)
Systemic antipsoriatic therapy may reverse endothelial dysfunction (2011) (3)
Initiative for quality in psoriasis and psoriatic arthritis. (2008) (3)
Plasma cells in the dermal infiltrate of mycosis fungoides are of polyclonal origin. (1989) (3)
Primary subcutaneous leiomyosarcoma exhibiting the characteristic immunophenotype positive for vimentin and desmin. (1994) (3)
GRAPPA Fellows Symposium Adjacent to the European Academy of Dermatology and Venereology (EADV) Congress, Istanbul, 2013: A Meeting Report (2014) (3)
Efficacy and Safety of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients With Active Psoriatic Arthritis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study (2017) (3)
Epidermal insulin resistance as a therapeutic target in acanthosis nigricans? (2014) (3)
Best-practice Indicators in Psoriatic Disease Care (2019) (3)
A majority of proliferating T cells in cutaneous malignant T cell lymphomas may lack the high affinity IL-2 receptor (CD25) (2005) (3)
GRAPPA Trainees Symposium 2017: A Report from the GRAPPA 2017 Annual Meeting (2018) (3)
Effects of rofecoxib, celecoxib, and parecoxib on anti‐IgE‐induced histamine release from human skin mast cells and basophils (2003) (3)
AB0820 COMPARATIVE EFFICACY OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS (2020) (3)
Adipose-Derived Stromal Cells for Chronic Wounds: Scientific Evidence and Roadmap Toward Clinical Practice (2022) (3)
Photodynamic effects on T-cells and skin lesions of a patient with mycosis fungoides using porphyrin photosensitizers (1994) (3)
[Treatment recommendations for psoriatic arthritis]. (2009) (3)
LOOP, a cross-sectional, observational study investigating the clinical specialty setting as a determinant of disease management in psoriatic arthritis: Subgroup analysis results from Japan (2021) (2)
Interleukin‐17E, inducible nitric oxide synthase and arginase1 as new biomarkers in the identification of neutrophilic dermatoses (2021) (2)
GRAPPA Trainees Symposium 2018: A Report from the GRAPPA 2018 Annual Meeting (2019) (2)
Etanercept: a soluble TNF-a receptor in the treatment of psoriasis (2007) (2)
Presidential Round Table: A Report from the GRAPPA Annual Meeting (2016) (2)
Clinical long‐term studies: data collection and assessment (2011) (2)
Assessment of publications using methods of evidence‐based medicine: an introduction using a dermatological clinical study (2007) (2)
SAT0397 GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAÏVE OR TNFΑ INHIBITOR-EXPERIENCED (2020) (2)
[Psoriasis in the animal model]. (1997) (2)
[Chronic leg ulcers and Pseudomonas aeruginosa infection]. (2015) (2)
Pathogenesis-oriented therapy of psoriasis using biologics (2022) (2)
IL-25 participates in keratinocyte-driven dermal matrix turnover and is reduced in Systemic Sclerosis epidermis. (2022) (2)
15281 Effects of guselkumab on articular components of American College of Rheumatology score and skin responses in patients with active psoriatic arthritis: Results from the phase 3 DISCOVER-2 study (2020) (2)
Comparitive in vitro effects of mono- and polychromatic photodynamic therapy on malignant transformed B- and T-cells (1993) (2)
[To be or not to be: another round in the discussion of the role of psoriasis as a risk factor for associated diseases]. (2013) (2)
[Human to mouse xenotransplantation models complement transgenic and know-out mice. Comment on the contribution by K. Sellheyser: Transgenic mice as models for skin diseases]. (1996) (2)
SAT0344 The effect of guselkumab on enthesitis: results from a phase 2 study in patients with active psoriatic arthritis (2018) (2)
GRAPPA Trainees Symposium 2019: A Report from the GRAPPA 2019 Annual Meeting (2020) (1)
Peak and baseline concentrations of fondaparinux during prophylactic therapy (2011) (1)
P262 Guselkumab, an anti-interleukin-23p19 monoclonal antibody, in patients with active PsA who were biologic-naïve or prior TNFα inhibitor-treated: week 24 results of a Phase 3, randomised, double-blind, placebo-controlled study (2020) (1)
Expression of the basal cell adhesion molecule (B-CAM) in human epidermis (1998) (1)
Summary of Minutes of the GRAPPA Meeting Adjacent to the American Academy of Dermatology 67th Annual Meeting (2011) (1)
Safety of guselkumab with and without prior TNF-α inhibitor treatment: Pooled results across four studies in patients with psoriatic arthritis. (2023) (1)
Psoriasis assessment tools in clinical trials. Discussion (2005) (1)
AB0753 COMPARING COMPOSITE MEASURES OF DISEASE ACTIVITY IN PSORIATIC ARTHRITIS: RESULTS FROM A RANDOMIZED PHASE 2 TRIAL WITH GUSELKUMAB (2019) (1)
GRAPPA Fellows Symposium Adjacent to the Swiss Psoriasis Day, Geneva, 2014: A Meeting Report (2015) (1)
FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS (2020) (1)
In vivo reflectance confocal microscopy: a useful non-invasive tool to assess the response to isolated limb perfusion for superficial pigmented melanoma in-transit metastatic disease. Report of a case (2017) (1)
Lymphocyte homing to the skin : immunology, immunopathology, and therapeutic perspectives (2004) (1)
[Case report: unusual clinical presentation of a follicular lymphoma]. (2014) (1)
Dermatologists’ Management of Psoriatic Arthritis: A Report from the 2014 GRAPPA Meeting (2015) (1)
[Comorbidities in psoriatic arthritis]. (2013) (1)
Discussion: Treatment of psoriatic arthritis and psoriasis (2005) (1)
In vivo fluorescence spectroscopy and imaging of ALA-induced endogenous porphyrins in skin after Er:YAG ablation of human stratum corneum (1994) (1)
[The dermatological indications of laser: beyond cosmetic target.] (2017) (1)
Supplementary Material for: Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry (2017) (1)
Idiopathic CD4+ T lymphocytopenia presenting as mycetoma in a patient with a mutation in the cystic fibrosis transmembrane regulator gene. (1996) (1)
Efficacy and safety of a patch containing adipose-derived stem cells for skin wound healing – results form a comprehensive pre-clinical evaluation program (2022) (1)
Within-individual comparison of Q-switched Nd:YAG and alexandrite lasers in the treatment of monochromatic black amateur tattoos (1994) (1)
Problemorientiertes Praktikum (POP) in der Dermatologie: eine Alternative? (1999) (1)
15325 Effects of guselkumab on musculoskeletal features in patients with active psoriatic arthritis by baseline skin disease: Results from the phase 3 DISCOVER-1 and DISCOVER-2 studies (2020) (1)
AB0745 ASSESSMENT OF DISEASE ACTIVITY USING RAPID3 AND EVALUATION OF TREATMENT EFFECT OF GUSELKUMAB IN PATIENTS WITH PSA: RESULTS FROM A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL (2019) (1)
377 IL-17E favors the recruitment of neutrophils in psoriasis via macrophage activation (2016) (1)
Schön et al. reply to “Efomycine M: an inhibitor of selectins?” (2006) (1)
Induction of proinflammatory molecules by anthralin is mediated via reactive oxygen species and activation of NF-KB in human keratinocytes (1998) (1)
SAT0322 The effect of guselkumab on dactylitis: results from a phase 2 study in patients with active psoriatic arthritis (2018) (1)
CUTANEOUS DELAYED-TYPE IV-HYPERSENSITIVITY REACTION (DTH) TO HEPARIN AND HEPARIN-INDUCED THROMBOCYTOPENIA TYPE II (HIT) - IS THERE AN ASSOCIATION ? (2007) (1)
Erratum: Leukocyte extravasation as a target for anti-inflammatory therapy - Which molecule to choose? (Experimental Dermatology (2005) vol. 14 (70-80)) (2005) (1)
[Dermatology: re-defining psoriasis]. (2015) (1)
[Therapy of psoriasis vulgaris with efalizumab]. (2006) (1)
Differential expression of heat shock proteins of the HSP70 family in human epidermis (1994) (1)
Epidermal structure and function. (2015) (1)
Application of photodynamic therapy in mycosis fungoides (1993) (1)
Use of delta opioid receptor agonists in the preparation of pharmaceutical compositions, pharmaceutical compositions containing them and their applications in treating tumors. (2006) (0)
SAT0345 Quality indicators in the care of psoriatic arthritis (2018) (0)
[New therapy option for problem patients. What is the value of "biologics" in psoriasis?]. (2004) (0)
Cutis marmorata teleangiectatica congenita with segmental distribution (1996) (0)
[Therapy of psoriasis-arthritis and psoriasis vulgaris with infliximab]. (2006) (0)
33064 Correlation of fatigue severity and psoriasis severity, and the treatment effect of guselkumab: A detailed analysis of SF-36 vitality scores from the VOYAGE 2 study (2022) (0)
Biologics in Psoriasis (2007) (0)
[Photodynamic therapy at the threshold of clinical use in disseminated dermatoses]. (1996) (0)
207 IL-17E (IL-25) alters epidermal homeostasis in a matter distinct from IL-17A (2019) (0)
A 41 year old man with an itchy rash (2011) (0)
[From competition to consultation]. (2013) (0)
27529 Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials (2021) (0)
AB0896 Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to a Systematic Literature Review and Network Meta-Analysis (2022) (0)
[Fumarates - far more than a dietary supplement]. (2018) (0)
Analysis of the T cell receptor Vα and Vβ repertoire in psoriasis (1994) (0)
AB0783 RELATIVE IMPACT OF JOINT AND SKIN SYMPTOMS ON QUALITY OF LIFE AND WORK PRODUCTIVITY IN PSORIATIC ARTHRITIS (PSA) PATIENTS (2019) (0)
The psoriasis xenograft SCID mouse model: a tool in translational research (2012) (0)
Author index (2005) (0)
AB0893 An Analysis of Fatigue in Patients With Psoriatic Disease Utilizing SF-36 Vitality Scores: Results Through Week 24 in Phase 3 Trials of Guselkumab in Patients With Psoriasis and Psoriatic Arthritis (2022) (0)
[Skin symptoms of psoriasis associated with spondylarthropathies]. (2016) (0)
High incidence of heparin-induced allergic skin reactions in pregnancy (2011) (0)
362 The role for epidermal αV integrin complexes in the pathogenesis of psoriatic inflammation (2022) (0)
27851 Efficacy of guselkumab (GUS) on axial-related endpoints in patients with active psoriatic arthritis (PsA) with imaging-confirmed sacroiliitis: Results through week 52 from DISCOVER-1 and DISCOVER-2 (2021) (0)
AB0125 IL-25 PARTICIPATES IN KERATINOCYTE-DRIVEN DERMAL MATRIX TURNOVER AND IS REDUCED IN SYSTEMIC SCLEROSIS (SSc) EPIDERMIS (2022) (0)
[Learning from each other, treating together]. (2021) (0)
Who will treat inflammatory skin diseases in the year 2020? (2018) (0)
Use of GABA B receptor selective agonists for the treatment of inflammatory skin diseases (2007) (0)
POS0082 A NOVEL PSORIATIC ARTHRITIS COMPOSITE ENDPOINT COMBINING TREATMENT TARGETS FOR SKIN AND JOINTS: POOLED RESULTS FROM THE GUSELKUMAB DISCOVER-1 AND DISCOVER-2 STUDIES (2022) (0)
P256 Treatment of psoriasis resistant to other modalities by topical photodynamic therapy (1997) (0)
Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial (Preprint) (2018) (0)
27847 Guselkumab (GUS) efficACy in TNF-inhibitor-experienced and TNF-inhibitor-naïve patients with active psoriatic arthritis (PsA): Results of a phase 3, randomized, controlled study (2021) (0)
Linkage between patients’ characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry (2019) (0)
Psoriasis-SCID-Maus-Modell (2006) (0)
AB0526 SUSTAINED GUSELKUMAB RESPONSE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS REGARDLESS OF BASELINE DEMOGRAPHIC AND DISEASE CHARACTERISTICS: POOLED RESULTS THROUGH WEEK 52 OF TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES (2021) (0)
[A plethora of choices: treating actinic keratoses]. (2020) (0)
[Tender livid papules]. (2004) (0)
SAT0289 THE INS AND OUTS OF EPIDERMAL DYSFUNCTION IN SYSTEMIC SCLEROSIS (SSC): RESULTS FROM A NOVEL TISSUE ENGINEERED EPIDERMAL EQUIVALENT FROM SSC KERATINOCYTES (2020) (0)
P027 Nail varnish allergy — A diagnosis easy to miss (1997) (0)
[Erythema scarlatiniforme desquamtivum recidivans or Féréol-Besnier disease: an uncommon condition]. (2013) (0)
Safety of systemic psoriasis treatments evaluated in the Swiss Dermatology Network for Targeted Therapies (SDNTT) (2017) (0)
[A beardless 34-year-old male patient]. (2004) (0)
P277 Assessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial (2020) (0)
LB1027 An adipose-derived stem cell-engineered patch represents a promising treatment for chronic wounds (2022) (0)
Contents Vol. 232, 2016 (2017) (0)
[Pre-auricular tumors in an infant. Differential diagnosis of neuroectodermal syndromes]. (2004) (0)
[Papules on the right lower leg of an African girl]. (2006) (0)
Skewed T cell receptor Vβ usage in nickel expanded peripheral blood T cells is due to an increase of nickel specific T cells (1994) (0)
POS1031 LOW INCIDENCE OF GASTROINTESTINAL-RELATED AND OVERALL SERIOUS ADVERSE EVENTS AMONG GUSELKUMAB-TREATED PATIENTS: POOLED ANALYSES OF VOYAGE 1 & 2 AND DISCOVER 1 & 2 THROUGH 1-YEAR (2021) (0)
Neue Therapieoption fur Problempatienten. Was bringen "Biologics" bei Psoriasis? (2004) (0)
Adhesion Receptors in Normal Skin and Cutaneous Malignant Lymphomas: Pathophysiological and Clinical Correlations (1994) (0)
Comprar Biologics in General Medicine | Boehncke, W.-H. | 9783540290179 | Springer (2007) (0)
POS1015 SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO ARE BIO-NAÏVE OR TNFi-EXPERIENCED: POOLED RESULTS FROM 4 RANDOMIZED CLINICAL TRIALS THROUGH 2 YEARS (2022) (0)
037 Safety of systemic psoriasis treatments evaluated in the Swiss Dermatology Network for Targeted Therapies (SDNTT) AutoreactiveB-cellsphenotypeanalysisinpemphiguspatientsbeforeandafteranti-CD20treatment Evaluation of mitochondria-organelle peptides versus nano-sized cellular extracts in aesthetic (2017) (0)
[Dermatology - the key to ensure a good long term clinical response]. (2016) (0)
IDIOPATHIC CD4+T LYMPHOCYTOPENIA PRESENTING AS MYCETOMA IN A PATIENT WITH A MUTATION IN A PATIENT WITH A MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR GENE (1996) (0)
[Heparins and skin reactions: from diagnostic to management]. (2013) (0)
Human herpesvirus-8 DNA in an immunocompetent patient with multifocal anglosarcoma of the face and scalp (1998) (0)
The T-cell receptor Vbeta repertoire of nickel-specific T cells. (1998) (0)
Molecular modelling of defensin bound to HLA- DR4 (1998) (0)
FRI0452 TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DERMATOLOGIC ENDPOINTS FROM 2 PHASE 3 STUDIES (2019) (0)
[A case of « peau d'orange » in the absence of cancer]. (2019) (0)
385 IL-17E activates M2 macrophages to produce IL-8 in a p38 dependent manner and favor the recruitment of neutrophils in psoriatic skin (2017) (0)
Elevating the Standard of Care for Patients with Psoriasis: ‘Calls to Action’ from Epicensus, a Multistakeholder Pan-European Initiative (2022) (0)
Inflammation modulates intercellular adhesion and mechanotransduction in human epidermis via ROCK2 (2022) (0)
[Cytokines IL-17, an expanding family used as a target for innovative anti-inflammatory therapies]. (2020) (0)
THU0306 Clinical specialty setting as a determinant for disease management in patients with psoriatic arthritis: results from loop, a cross-sectional, multi-country, observational study (2018) (0)
>>> Diagnose: Cutis verticis gyrata (2004) (0)
Controversies in experimental dermatology. Is psoriasis a T-cell disease? Commentaries (2000) (0)
[Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept]. (2005) (0)
[Nail changes : diagnostic considerations in everyday medical general practice]. (2017) (0)
Insulin Resistance may be a Central Pathogenetic Mechanism in the Development of Psoriatic Plaques (2012) (0)
[The role of bacterial superantigens in pathophysiology of the skin]. (1999) (0)
AB0749 Impact of Patient Perception of Psoriasis and Psoriatic Arthritis Severity on Patient-Reported Outcomes: An Analysis from The Adelphi Database (2016) (0)
Nordic Psoriasis Debate 2011: Managing Psoriasis - How Can I Improve Care for my Patients? An Interactive Debate on New Treatment Options for Psoriasis (2012) (0)
AB0538 POOLED SAFETY RESULTS FROM TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH 1 YEAR (2021) (0)
Announcement of the winners of the 1997 Munksgaard and Journal of Cutaneous Pathology Prize (1998) (0)
[100 years of Dermatology in French-speaking Switzerland]. (2014) (0)
Adipose-Derived Stromal Cells within a Gelatin Matrix Acquire Enhanced Regenerative and Angiogenic Properties: A Pre-Clinical Study for Application to Chronic Wounds (2023) (0)
Staphylococcal enterotoxin a induces epidermal changes distinct from staphylococcal enterotoxins B and C in the SCID-hu xenogeneic transplantation model (1998) (0)
[Psoriatic arthritis: important aspects for the dermatological practice]. (2021) (0)
113 Psoriatic inflammation modulates mechanotransduction and cell adhesion in human epidermis (2021) (0)
Evaluation for Comorbidities Important in Psoriasis (2014) (0)
[Child with atopy]. (2004) (0)
Phenotypic Heterogeneity of the Dermal Monocyte/Macrophage System (2019) (0)
[Switching from atopic dermatitis to psoriasis - and back]. (2021) (0)
Supplementary Material for: Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT (2017) (0)
Evidence for a psoriasis susceptibility gene linked to HLA-Cw6 in the extended haplotype HLA -DQB1∗0303, -DQA1∗0201, -DRB1∗0701, -B57, -Cw6 (1994) (0)
[Comorbidities in psoriasic arthritis]. (2014) (0)
PO-65 Incidence and causes of heparin-induced skin lesions – results of a prospective investigation (2010) (0)
PO-74 Allergic skin lesions are a rare adverse event under anticoagulant therapy with fondaparinux – results of a prospective investigation (2010) (0)
[Repurposing of betablockers in dermatology]. (2018) (0)
Acknowledgement to Referees for Dermatology 2016 (2017) (0)
Expression of Basal-Cell Adhesion Molecule (B-CAM) in Human Epidermis (2001) (0)
042 Evaluation of mitochondria-organelle peptides versus nano-sized cellular extracts in aesthetic dermatology: Comparative case study (2017) (0)
SAT0387 CONSISTENT EFFICACY IN PATIENT SUBGROUPS ACROSS BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS: RESULTS FROM A PHASE 2 STUDY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (2019) (0)
Induction of acantholytic blisters by autoantibodies from pemphigus patients in the SCID-hu xenogeneic transplantation model (1998) (0)
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study (2023) (0)
Application of photodynamic therpy in psoriasis (1993) (0)
369 An Adipose-derived Stem Cell-engineered matrix represents a promising treatment for chronic wounds (2021) (0)
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis (2022) (0)
Paradoxical nail psoriasis induced by the IL-17A inhibitor ixekizumab in palmoplantar pustulosis. (2023) (0)
FRI0440 THE EFFECT OF GUSELKUMAB ON PASDAS, GRACE INDEX, MCPDAI, AND DAPSA: RESULTS FROM A PHASE 2 STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (2019) (0)
[Progressive alopecia with pruritus]. (2004) (0)
Monozygotic twins concordantly affected by psoriasis exhibit a similar shift in the T-cell receptor Vβ-repertoire of lesional compared to circulating lymphocytes (1996) (0)
Supplementary Material for: Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris (2016) (0)
DRUG EVALUATION Etanercept: a soluble TNF-α receptor in the treatment of psoriasis (2007) (0)

This paper list is powered by the following services:

Wolf-henning Prof. Dr. Boehncke's Academic­Influence.com Rankings

Wolf-henning Prof. Dr. Boehncke's Degrees

Why Is Wolf-henning Prof. Dr. Boehncke Influential?

Wolf-henning Prof. Dr. Boehncke's Published Works

Published Works

Wolf-henning Prof. Dr. Boehncke's AcademicInfluence.com Rankings